Compare Nerdwallet Inc (NRDS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Zoetis Inc — how do they compare? Nerdwallet Inc trades at $9.22 (market cap $603.70M), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 52.9× Nerdwallet Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| NRDS | ZTS | |
|---|---|---|
Market Cap | $603.70M | $31.95B |
Sector | Financials | Health |
52-Week High | $15.93 | $156.76 |
52-Week Low | $7.58 | $71.91 |
Enterprise Value | $518.00M | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRDS trades at $9.12, down 1.51% today, with a bearish technical signal but strong fundamentals including a 93% gross margin and consistent earnings beats. Revenue grew to $836.6M in 2025, with net income reaching $48.7M. Positive analyst sentiment includes a $12.75 consensus target, though technical indicators show near-term pressure.
The stock offers value with a P/E of 9.87 and upside potential from analyst targets, but faces risks from competitive pressures and reliance on consumer financial health. Earnings growth and margin expansion are key catalysts, yet macroeconomic sensitivity could impact performance.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
